FLT1), VEGFR-2 (fetal liver kinase 1 (FLK1), KDR), and VEGFR-3 (fms-like tyrosine kinase-4, FLT-4). VEGFR-1 primarily mediates endothelial cell and monocyte migration, 6, 7) whereas VEGFR-2 is considered as a potent angiogenic factor that mediates the proliferative and mitogenic activities of VEGF. 8, 9) VEGFR-3 is primarily associated with lymphogenesis.
10) VEGFR-2 is exclusively expressed in endothelial cells and appears to play a pivotal role in endothelial cell differentiation and vasculogenesis in human malignant diseases, indicating that VEGFR-2 may be a target for suppression of tumor growth. 11) There is accumulating evidence that the persistence and growth of lung carcinomas and their metastasis are angiogenesis dependent. 12, 13) Moreover, the VEGF/VEGFR-2 signaling pathway is regarded as playing an important role in the development and progression of lung carcinoma. [14] [15] [16] Hence, antiangiogenic therapy targeting VEGFR-2 (FLK1, KDR) might represent a good alternative for the treatment of lung carcinoma.
After discovering some antigens based of activated endothelial cells in tumor angiogenesis are capable of inducing protective immunity, immunotherapy against endothelial cells has begun to play an important role in cancer treatment. 17, 18) Some studies have shown that immunization with plasmid DNA encoding angiogenesis-related antigens can inhibit tumor associated angiogenesis. [19] [20] [21] [22] These DNA vaccines can induce either antigen-specific humoral or cellular immune responses. The vaccination procedure generated antibodies or T-cell-mediated cytotoxicity against the targeted cells can inhibit tumor growth and lead to tumor rejection. 19, 22) Several studies have used DNA vaccine encoding the full length FLK1 gene to inhibit tumor-associated angiogenesis. 23, 24) However, the full length FLK1 gene utilized in these studies was about 4 kb, encoding for a protein of approximately 190 kDa, and is most likely a mutation introduced during vaccine production. Mutation can also occur in the host once plasmids encoding these genes are delivered by Salmonella typhimurium to secondary lymphoid tissues such as Peyer's patches in the small intestine. For this reason, more defined vaccines encoding a smaller FLK1 gene were employed to create a simpler immune response. [25] [26] [27] The full length VEGFR-2 gene contains an extracellular region, a transmembrane domain, and a tyrosine kinase domain. The extracellular region of VEGFR-2 consists of 7 immunoglobulin-like domains. The third one is critical for ligand binding, and the second and fourth domains are important for ligand association. Some studies have shown that antibodies against the extracellular region of VEGFR-2 could inhibit tumor angiogenesis, 28, 29) while other studies have suggested that the DNA vaccine encoding peptides from the self-VEGFR-2 extracellular region could induce the specific cellular immune response to FLK1. 27, 30) On the basis of the important function of the extracellular region of VEGFR-2 in generating antiangiogenesis immunity, we hypothesized that selecting the extracellular domain of FLK1 as a target could induce a sufficient anti-FLK1 immune response.
In this regard, we prepared a DNA vaccine encoding the complete extracellular domain of the FLK1 gene carried by attenuated S. typhimurium, and the vaccine was tested for the ability to induce anti-FLK1 immune responses and to inhibit tumor-induced angiogenesis in the Lewis lung cancer mouse model.
MATERIALS AND METHODS

Animals, Bacterial Strains, and Cell Lines
Female C57BL/6J mice, aged 6 to 8 weeks, were purchased from Vitalriver Inc., Beijing, China, and maintained in our animal laboratory facility. The animal certificate number was "SCXK (Beijing) 2002-0003." All animal studies were performed in accordance with the guidelines for animal care established by Kunming Medical University's Animal Care and Use Committee. The attenuated S. typhimurium strain SL3261 (aroA mutant) was kindly provided by Dr. Ji Fen Bian of the Experimental Center of Medical Molecular Biology in Shandong University, China and bacteria were routinely grown at 37°C in LB broth or on agar plates, supplemented, when required for selection, with 100 mg/ml ampicillin. The murine Lewis lung carcinoma cell line (3LL) was purchased from Shanghai Institute of Thoracic Tumors, Shanghai Chest Hospital Shanghai, China. The mouse pancreatic islet endothelial cells (MS1) were a gift from Professor Marie C. Lin of the Department of Chemistry, Hong Kong University, Hong Kong.
Gene Cloning and Construction of Expression Vector for DNA Vaccination The DNA encoding sequence of the extracellular domains (ECD) of VEGFR-2 was amplified with upstream primer 5Ј-GATAACCTGGCTGACCCG-ATTC-3Ј and downstream primer 5Ј-GCTCTAGATTA-TTCCAAGTTGGTCTTTTCC-3Ј by reverse transcription polymerase chain reaction (RT-PCR) from C57BL/6 mice embryo and cloned with upstream primer 5Ј-CCGGTA-CCATGGAGAGCAAGGCGC-3Ј and downstream primer 5Ј-GCTCTAGATTATTCCAAGTTGGTCTTTTCCTG-3Ј by polymerase chain reaction (PCR). The PCR products were then inserted into the pcDNA3.1 (ϩ) vector (Invitrogen Corp., Carlsbad, California, U.S.A.) between the restriction sites KpnI and XbaI to generate pcDNA3.1-FLK1 ECD . Protein expression was demonstrated by Western blotting analysis of transfected COS-7 cells with goat anti-mouse VEGFR-2 monoclonal antibody (R&D Systems Inc., Minneapolis, Minnesota, U.S.A.). Bacteria were transformed to generate the orally administered DNA vaccine as described. 31) Immunization Procedure and Tumor Challenge Mice were immunized by oral gavage 3 times at 2-week intervals with 100 ml sodium bicarbonate (NaHCO 3 ) buffer containing 1ϫ10 8 colony formation units (CFUs) of S. typhimurium transformed with pcDNA3.1-FLK1 ECD or pcDNA3.1-enhanced green fluorescent protein (EGFP), respectively. NaHCO 3 was used as a negative control. Mice were challenged 2 weeks later by subcutaneous (s.c.) injection of 1ϫ10 6 live 3LL cells into the left front flank. Tumor volume was measured in 2 dimensions and calculated as follows: Tumor volumeϭp/6ϫlengthϫwidth 2 . For experimental pulmonary metastasis, 5ϫ10 5 live 3LL cells were intravenously injected into the tail veins of C57BL/6J mice 2 weeks after the last immunization. When control mice became moribund, subcutaneous tumors were harvested for detection of micro vessel density (MVD), and the lungs were removed and analyzed for metastasis.
Detection of Antibody Response Mice were immunized 3 times with pcDNA3.1-FLK1 ECD , pcDNA3.1-EGFP and NaHCO 3 . Blood samples were collected 7 d after the vaccinations. Anti-FLK1 immunoglobulin G (IgG), IgG2a, IgG2b and IgG1 in the sera were detected by enzyme linked immunosorbent assay (ELISA). Briefly, microtiter plates were incubated with 100 ng per well of purified murine VEGFR-2 protein (R&D Systems Inc., Minneapolis, Minnesota, U.S.A.) in 0.05 M sodium bicarbonate buffer overnight at 4°C. After three washes with 0.1% Tween in PBS, 2% BSA was added to the plate and incubated at room temperature for 1 h. Diluted (1 : 100) sera were then added to the wells and incubated for 1 h. Wells were washed 3 times and then incubated with 100 ml horseradish peroxidase conjugated goat anti-mouse IgG, IgG2a, IgG2b and IgG1 (Thermo Fisher Scientific, Rockford, IL, U.S.A.) respectively for 1 h. Wells were washed 3 times and then incubated with 50 ml of 3,3,5,5-tetra-methylbenzidine (TMB) substrate (Kirkegaard & Perry Laboratories Inc., Gaithersburg, Maryland, U.S.A.) for 15 min. The reaction was stopped by adding 50 ml of 1 M phosphoric acid and then the wells were read at 490 nm on a microtiter plate spectrophotometer.
Detection of Intracytoplasmic Cytokines Mice were immunized 3 times with pcDNA3.1-FLK1 ECD , pcDNA3.1-EGFP and NaHCO 3 . Splenocytes obtained from the immunized or control mice were suspended in RPMI 1640 supplemented with 10% FBS and incubated with the purified murine VEGFR-2 protein (R&D Systems Inc., Minneapolis, Minnesota, U.S.A.) at a concentration of 2 mg/ml for 24 h. Monensin (100 mg/ml; Sigma, St. Louis, MO, U.S.A.) was added to each well and blocked at 37°C for 3 h. The splenocytes were then suspended in phosphate buffered salin (PBS) and stained with PC5-labeled anti-mouse CD3 antibody, RD1-labeled anti-mouse CD4 antibody, and ECDlabeled anti-mouse CD8 antibody (Beckman Coulter Inc., Fullerton, California, U.S.A.) for 20 min in the dark. After one wash with PBS, the cells were fixed, permeabilized, and stained with fluorescein isothiocyanate (FITC)-labeled antimouse interferon-g (IFN-g) antibody or FITC-labeled antimouse interleukin-4 (IL-4) antibody (Beckman Coulter Inc., Fullerton, California, U.S.A.) for 30 min at room temperature. Samples were analyzed in a Beckman Coulter EPICS XL flow cytometer (Beckman Coulter Inc.).
In Vitro Cytotoxicity Assay For the determination of the possible FLK1 specific cytotoxicity mediated by cytotoxic T-lymphocytes (CTLs), a 4-h standard 51 Cr release assay was performed as described. 32) Briefly, 3LL tumor cells or FLK1-positive murine pancreatic islet endothelial cells (MS1) were used as target cells. Splenocytes obtained from the immunized or control mice were prepared by passing through cell strainers and treated with ammonium chloride to deplete erythrocytes. Effector cells (100 ml) and 51 Cr-labeled target cells were assigned at different E : T (effector-target) ratios to each well of microtiter plates and were incubated at 37°C for 4 h. The percentage cytotoxicity was calculated using the formula: (experimental releaseϪspontaneous release)/(maximum releaseϪspontaneous release)ϫ100.
Immunohistochemistry Tumor specimens were fixed in 10% neutral buffered formalin for 12 h and standard dehydration and paraffin-wax embedding procedures were used on fixed tissues. Four-micrometer-thick sections of representative blocks from each mouse were dewaxed in xylene, rehydrated through descending concentrations of alcohol, and treated with 0.3% hydrogen peroxide in methanol for 5 min to block the endogenous peroxidase activity. The sections were then washed in PBS and subjected to heat-induced epitope retrieval in 1 mM ethylenediaminetetraacetic acid (EDTA) (pH 8.0). Sections were incubated with a rat antimouse CD31 monoclonal antibody (Chemicon International Inc, Temecula, CA, U.S.A.; 1 : 100 dilution) at 4°C overnight. Immunoreactions were then performed according to the instruction manual for the streptavidin-biotin staining kit (UltraSensitive TM S-P kit, Maxim Biotech Inc., Fuzhou, China). The reaction product was developed by using 3,3Ј-diaminobenzidine tetrahydrochloride (DAB, Maxim Biotech Inc., Fuzhou, China) and then counterstained with hematoxylin. PBS was used instead of the primary antibodies for negative controls. MVD were assessed as previously described. 33) In the areas that were considered to be most active for neovascularization, stained vessels were counted in a ϫ200 microscopic field (Olympus BH-2 microscope, 0.74 mm CFUs of S. typhimurium harboring either pcDNA3.1-EGFP or pcDNA3.1 vectors by oral gavage. The animals were sacrificed 7 d after the inoculation and the small intestines and spleens were collected. Five Peyer's patches and the whole spleen from each mouse were homogenized and serially diluted in PBS. EGFP-expressing cells were detected by flow cytometry.
Statistics Statistical significance was analyzed by Student's t-test and ANOVA. Survival curves were constructed according to the Kaplan-Meier method and statistical significance was determined by the log-rank test. SPSS 10.0 software was used in all statistical tests. (Fig. 1A) . (Fig. 1B) .
RESULTS
Cloning and Analysis of pcDNA3.1-FLK1 ECD
Immune Tolerance to Self-FLK1 Antigen Could Be Broken by Immunization with pcDNA3.1-FLK1 ECD To analyze the humoral immune response in mice immunized with pcDNA3.1-FLK1 ECD , sera were collected from immunized mice and tested for anti-FLK1 antibody by ELISA in plates coated by FLK1. A strong antibody response was generated in pcDNA3.1-FLK1 ECD vaccinated mice. FLK1-specific total IgG antibody titer was significantly higher in all mice vaccinated with pcDNA3.1-FLK1 ECD compared with control mice. Th1-related subclasses IgG2a and IgG2b but not Th2-related IgG1 antibody responses were induced in mice vaccinated with pcDNA3.1-FLK1 ECD . In contrast, anti-FLK1 IgG2a, IgG2b and IgG1 were not detected in any control mice (Fig. 2A) . These results indicate that immunization with pcDNA3.1-FLK1 ECD can induce antigen-specific Th1-type humoral immune responses in mice.
Next, to determine the effect of pcDNA3.1-FLK1 ECD on the patterns of cytokine production, splenocytes from mice were used to quantify the production of IFN-g and IL-4 by flow cytometry. The IFN-g secreting CD3 ϩ
CD4
ϩ T-cells (A) Sera collected from mice were diluted (1 : 100) and analyzed for anti-FLK1 IgG, IgG2a, IgG2b and IgG1 antibody using ELISA in plates coated with FLK1. FLK1-specific total IgG antibody, and Th1-related subclasses IgG2a and IgG2b antibody titer were significantly higher in mice vaccinated with pcDNA3.1-FLK1 ECD () compared with the pcDNA3.1-EGFP ( ) and NaHCO 3 groups (ᮀ) (pϽ0.01). There were no differences in the Th2-related IgG1 antibody level between the pcDNA3.1-FLK1 ECD immunized (), pcDNA3.1-EGFP ( ) and NaHCO 3 groups (ᮀ) (pϾ0.05). compared with the control group (Fig. 2C) . To determine whether this CTL response was specific for FLK1, T-cells from the pcDNA3.1-FLK1 ECD immunized group were also tested against MS1 or 3LL cells as targets. Only the FLK1-positive endothelial target cell line (MS1) but not the FLK1-negative target cell line (3LL) was lysed by these T-cells, indicating the specificity for FLK1 antigen (Fig. 2D) . These results indicate that vaccination with pcDNA3.1-FLK1 ECD can result in induction of specific Th1-type cellular immune responses and antigen-specific CTL responses in mice.
DNA Vaccine Inhibits Tumor Growth and Prolongs the Lifespan of Mice
Marked inhibition of tumor growth was observed in C57BL/6J mice challenged 2 weeks after the third boost vaccination with pcDNA3.1-FLK1 ECD by s.c. injection of murine 3LL Lewis lung carcinoma cells. In contrast, control animals exhibited uniformly rapid tumor growth (Fig. 3A) . Mice (nϭ6) challenged 2 weeks after the third vaccination with pcDNA3.1-FLK1 ECD by s.c. injection of murine 3LL Lewis lung carcinoma cells also showed a significant increase in lifespan compared to control mice (Fig. 3B) .
Vaccination with pcDNA3.1-FLK1 ECD Inhibits Tumor Neovascularization Tumor blood vessel analysis was performed by immunohistochemical study using an antibody specific for CD31. Tumor microvessel density (MVD) was found to be significantly reduced in tumors taken from mice vaccinated with pcDNA3.1-FLK1 ECD compared to tumors from mice vaccinated with pcDNA3.1-EGFP and NaHCO 3 (Fig. 4) .
Vaccination with pcDNA3.1-FLK1 ECD Inhibits Lewis Lung Pulmonary Metastasis To determine whether active immunization against FLK1 could inhibit tumor metastasis, we tested immunized mice in an experimental metastasis model of Lewis lung carcinoma. Mice immunized with pcDNA3.1-FLK1 ECD developed significantly reduced lung weight and decreased numbers of metastases in the lungs compared with control mice (Figs. 5A, C) . The weight of lungs in pcDNA3.1-FLK1 ECD immunized mice was similar to that of no intervention mice (normal). Histological examination showed no evidence of micrometastasis in several mice (6 of 10) immunized with pcDNA3.1-FLK1 ECD , whereas all mice in the control group developed extensive pulmonary metastases (Fig. 5B) . In addition to examination of tumor metastasis in immunized mice, a similar experiment was conducted to evaluate the effect of pcDNA3.1-FLK1 ECD immunization on survival. While all mice had died by day 24 in the control group, 66% of the mice in the pcDNA3.1-FLK1 ECD group still survived by day 50 (Fig. 5D) . These results suggest that in addition to affecting the growth of a subcutaneous implanted tumor, pcDNA3.1-FLK1 ECD also inhibits 
CD4
ϩ T-cells (pϽ0.01) (Fig. 6A) and CD3 ϩ
CD8
ϩ T-cells (pϽ0.01) (Fig.  6B) compared with the pcDNA3.1-EGFP group and NaHCO 3 group. Notably, the CD4/CD8 ratio in control mice was significantly decreased, whereas immunization with pcDNA3.1-FLK1 ECD resulted in the presence of normal levels (Fig. 6C ). These results demonstrate that mice can be protected by pcDNA3.1-FLK1 ECD immunization after challenge with Lewis lung carcinoma cells.
S. typhimurium-Mediated Transgene Expression in Secondary Lymphoid Organs
To determine the expression of the gene delivered by the orally administered S. typhimurium carrier, mice were fed the SL3261 strain harboring either pcDNA3.1-EGFP or pcDNA3.1 vectors. Approximately 36.5% of the homogenized Peyer's patches of mice treated with pcDNA3.1-EGFP were scored as positive for EGFP expression. In contrast, only 3.99% of the homogenized Peyer's patches of mice treated with pcDNA3.1 were scored as positive for EGFP expression (Fig. 7A) . Moreover, approximately 14.3% of the splenocytes of mice treated with pcDNA3.1-EGFP were scored as positive for EGFP expression. In contrast, only 2.37% of the splenocytes of mice treated with pcDNA3.1 were scored as positive for EGFP expression (Fig. 7B) . These data suggest that this attenuated strain of S. typhimurium can transfer the respective plasmid to Peyer's patches, and such plasmids encoding the target gene can still express the respective protein in secondary lymphoid organs.
DISCUSSION
There is widespread consensus that angiogenesis is strongly associated with the progression of the majority of cases of non-small cell lung cancer (NSCLC) and is regulated by complex mechanisms in the presence of various angiogenesis related molecules. [34] [35] [36] [37] [38] Many molecules were overexpressed or new different molecules were expressed specifically in the endothelial cells of solid tumors compared with those in mature blood vessels during angiogenesis. These molecules can bind with their ligands and trigger the downstream signaling processes of angiogenesis. DNA vaccination may be used to target these molecules associated with tumor angiogenesis, and it is an appropriate tactic for vaccine development to prevent tumor growth and metastasis. 18) In addition, because DNA vaccines can be easily and cheaply produced and purified in large quantities, and do not require special handling or storage conditions, DNA vaccines have become a powerful vaccine strategy in cancer immunotherapy.
In this study, we chose FLK1, whose importance in lung carcinoma angiogenesis is recognized, as the molecular target with which to analyze whether a DNA vaccine encoding the complete extracellular domain of FLK1 gene delivery by S. typhimurium could provoke anti-FLK1 immune responses and prevent tumor-induced angiogenesis in a Lewis lung cancer model in mice. We found that oral immunization with the DNA vaccine could break the tolerance to self-antigen and inhibit lung carcinoma angiogenesis and metastasis. Our data are consistent with those of another study that used DNA vaccine encoding the full length FLK1 gene to inhibit tumorassociated angiogenesis. 23) A vaccine of dendritic cells pulsed with autologous protein of extracellular domain of FLK1 was also used to break the tolerance against self molecules. 32) These results provide strong proof to support the concept that the immune response against angiogenic targets could be elicited by breaking immune tolerance to self-antigens and could be effectively used for cancer therapy. The attenuated S. typhimurium bacterial strain may be an efficient gene delivery system in this process.
In the current study, our results showed that both FLK1 specific humoral and cellular immune responses against endothelial cells could be induced in mice by immunization with pcDNA3.1-FLK1 ECD . A high level of FLK1-specific IgG antibody was detected in the sera of pcDNA3.1-FLK1 ECD immunized mice, whereas no antibody was detected in control mice. We also determined the subclasses of FLK1-specific IgG antibody induced by the DNA vaccines. Th1-related subclasses IgG2a and IgG2b but not Th2-related IgG1 antibody responses were induced in the mice vaccinated with the pcDNA3.1-FLK1 ECD . A previous study reported that the production of IgG1 type was induced by Th2-type cytokines and that the IgG2a and IgG2b isotypes were regulated by Th1-type cytokines. 39) These results indicate that our DNA vaccination resulted in induction of FLK1-specific IgG and that subclasses of antibody appeared to be involved in Th1-type cellular immune responses in immunized mice.
The patterns of cytokines released by T-cells reflect the direction of the immune response. Thus, we examined the intracytoplasmic IFN-g and IL-4 cytokine production in FLK1 stimulated T-cells. We found that the IFN-g secreting CD3 
CD4
ϩ T-cells (Th2) were not detected in either pcDNA3.1-FLK1 ECD immunized or control mice. A previous study has shown that IFN-g, a prototypical Th1-type cytokine, is produced predominantly by CD4 ϩ Th1 cells and CD8
ϩ T-cells, and the level of IFN-g expressed by stimulated T-cells reflects the magnitude of the T-cell response. 40) On the other hand, IL-4 is a prototypical Th2-type cytokine that plays a dominant role in B-cell mediated immune responses. 41) These results indicate that pcDNA3.1-FLK1 ECD vaccination results in the induction of specific and potent Th1-type cellular immune responses in mice. We also examined the levels of antigen-specific CTL responses after immunization. The animals immunized with pcDNA3.1-FLK1 ECD showed positive CTL activities. However, only a background level of specific killing was observed from the control mice. In addition, an analysis of this CTL response was also tested for FLK1 specificity. Only the FLK1-positive endothelial target cell line (MS1) but not the FLK1-negative target cell line (3LL) was lysed by these T-cells, indicating the specificity for FLK1 antigen. In agreement with the activation of T-cell mediated immune responses, the percentages of CD3 ϩ
ϩ and CD3 ϩ CD8 ϩ T-cells were increased in mice treated with pcDNA3.1-FLK1 ECD , and the CD4/CD8 ratio in pcDNA3.1-FLK1 ECD immunized mice was significantly higher than that of control mice after 3LL tumor cells were injected. Taken together, these results demonstrate that this DNA vaccine strategy generates potent antigen-specific humoral and cellular immune responses in vivo, and mice can be protected by immunization after challenge with tumor cells.
In view of the advantage of DNA vaccine in the present study results, we conclude that a DNA vaccine strategy that targets FLK1 may be a useful approach to inhibit lung carcinoma and other solid tumor angiogenesis. The plasmid DNA vaccine encoding the extracellular domain of FLK1 could be an important component of FLK1 DNA vaccine to prevent lung carcinoma recurrence and metastasis after surgery.
